Boston Scientific Announces Positive Late-Breaking Data From The INTREPID Study

MARLBOROUGH, Mass., April 24, 2018 -- (Healthcare Sales &Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) today announced one-year data from the INTREPID study, the first and only prospective, double-blind, randomized, sham-controlled, mul... Devices, Neurology Boston Scientific, INTREPID study, deep brain stimulation, Parkinson's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Contributors : Lilach Soreq ; Hagai Bergman ; Zvi Israel ; Hermona SoreqSeries Type : Non-coding RNA profiling by arrayOrganism : Homo sapiens ; synthetic constructParkinson's disease (PD) is a prevalent, multifaceted neurodegenerative disease caused by mostly unknown factors. MicroRNAs (miRNAs) are small (~21 nucleotides long) RNAs that regulate up to hundreds of target genes. To study the role of miRNAs in PD and following surgical brain electrical stimulation treatment response, the expression profiling of miRNAs in peripheral blood leukocyte cells of PD patients pre- deep brain stimulation (DBS) and post-DBS both on el...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by array Homo sapiens synthetic construct Source Type: research
Pure akinesia with gait freezing (PAGF) is a variant of progressive supranuclear palsy, poorly responsive to pharmacological treatment and mainly characterized by prominent freezing of gait and dysarthria. Extradural motor cortex stimulation (EMCS) is a safe neurosurgical procedure [1], which may improve axial motorsymptoms of Parkinson's disease (PD) [2] and might represent a therapeutic option in patients with movements disorders not eligible for deep brain stimulation (DBS) [3,4].
Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation - Category: Neurology Authors: Source Type: research
To the Editor We read with interest the article by Gratwicke et al that described deep brain stimulation of the nucleus basalis of Meynert (NBM DBS) and the potential symptomatic effects in patients with Parkinson disease dementia. No consistent improvements were observed in the primary cognitive outcomes. However, the authors found evidence of improvements in neuropsychiatric symptoms, probably driven by a reduction in complex visual hallucinations. Although modest, these findings encourage further DBS research in this subgroup of patients.
Source: JAMA Neurology - Category: Neurology Source Type: research
In Reply We thank de Castro dos Santos et al for their letter and their interest in our article. They question whether current spread to the optic tract may account for the decrease in the reported severity of visual hallucinations. The optic tract lies inferomedial to the globus pallidus internus. Deep brain stimulation (DBS) that spreads to the optic tract causes patients to experience visual perceptions commonly referred to as “flash.” None of the patients in our study reported this phenomenon either at 20-Hz or 130-Hz test stimulation. This was not a surprise to us, given that the postoperative verification...
Source: JAMA Neurology - Category: Neurology Source Type: research
CONCLUSIONS The results of this study demonstrate that the software can reliably and accurately estimate entry into and exit from the STN and select the track corresponding to ultimate DBS implantation. PMID: 29775152 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - Category: Neurosurgery Authors: Tags: J Neurosurg Source Type: research
A new multiple-source system for deep-brain stimulation in patients with Parkinson's disease proved effective in the randomized, double-blind INTREPID trial.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Authors: Mehanna R, Fernandez HH, Wagle Shukla A, Bajwa JA PMID: 29755729 [PubMed]
Source: Parkinsons Disease - Category: Neurology Tags: Parkinsons Dis Source Type: research
Okun (2012).New England Journal of Medicine.Deep brain stimulation (DBS) of the subthalamic nucleus inParkinson's disease (PD) has been highly successful in controlling the motor symptoms of this disorder, which include tremor, slowed movement (akinesia), and muscle stiffness or rigidity. The figure above shows the electrode implantation procedure for PD, where a stimulating electrode is placed in either thesubthalamic nucleus, (STN), a tiny collection of neurons within the basal ganglia circuit, or in the internal segment of theglobus pallidus, another structure in the basal ganglia (Okun, 2012). DBS of the STN is more co...
Source: The Neurocritic - Category: Neuroscience Authors: Source Type: blogs
High frequency ( ∼130 Hz) deep brain stimulation (DBS) of the subthalamic region is an established clinical therapy for the treatment of late stage Parkinson's disease (PD). Direct modulation of the hyperdirect pathway, defined as cortical layer V pyramidal neurons that send an axon collateral to the subthalamic nucleus (STN), has emerged as a possible component of the therapeutic mechanisms. However, numerous questions remain to be addressed on the basic biophysics of hyperdirect pathway stimulation.
Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation - Category: Neurology Authors: Source Type: research
This study sought to do so in a sample of patients with PD (N  = 31) who underwent deep brain stimulation (DBS) surgery for motor symptom treatment.
Source: Journal of Psychosomatic Research - Category: Psychiatry & Psychology Authors: Source Type: research
More News: Brain | Deep Brain Stimulation | Marketing | Neurology | Neuroscience | Parkinson's Disease | Pharmaceuticals | Study